News

“We believe that Tafa–Len–R-CHOP is a potential new standard for frontline intermediate or high-risk DLBCL or HGBL,” said Georg Lenz, MD.

SUCCESSOR-2 shows oral mezigdomide plus carfilzomib/dexamethasone extends PFS to 18 months in high-risk relapsed myeloma.

"The key finding is that more axillary surgery in itself does not improve survival in these patients," said Jana de Boniface, MD, PhD.

“Further investigation of intravesical rBCG in combination with next-generation systemic regimens in randomized trials is warranted,” said Richard Cathomas, MD.

Notably, patients in EV-302 who converted from PR to CR achieved survival outcomes similar to those who achieved CR directly.

Belantamab plus VRd in newly diagnosed myeloma yields response rates over 85% with dose schedules to manage ocular toxicity.

ROSELLA update shows consistent OS benefit with relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, irrespective of prior taxane use.

Long-term RUBY data show dostarlimab plus chemo drives durable remission and potential cure in many dMMR/MSI-H advanced or recurrent endometrial cancer patients.

FDA grants orphan drug status to EO2463 vaccine for watch-and-wait indolent NHL, advancing a potential treatment option and spotlighting promising SIDNEY trial data.

FLAIR finds ibrutinib‑rituximab matches FCR quality of life in untreated CLL over 4 years, with distinct adverse‑effect tradeoffs.

The phase 3 POTOMAC study was the supporting trial for the FDA approval of the durvalumab combination for BCG-naive NMIBC.

FDA fast tracks STX-0712, a CCR2-targeted CyTAC, as phase 1 trial enrolls to tackle relapsed/refractory CMML and monocytic AML.

Treatment with the ADC pivekimab sunirine can be initiated in an outpatient setting.

Phase 3 NEOTORCH shows perioperative toripalimab plus platinum chemo boosts event-free survival and responses in resectable stage II–III NSCLC.

FDA grants priority review to neladalkib for post-TKI ALK+ NSCLC, aiming to beat resistance and brain metastases; decision due Nov 27, 2026.

New survey reveals CLL physicians and patients vary widely on post-BTK inhibitor tradeoffs, urging shared decisions beyond survival data.

FDA opens expanded access to daraxonrasib for metastatic pancreatic cancer, as phase 3 data boost survival and clinics race to manage access hurdles.

FDA extends camizestrant review as ctDNA-guided ESR1 switch sparks debate; new analyses debut at ASCO while Europe advances approval.

Oncologists weigh second-line options after ICI failure in metastatic ccRCC, spotlighting lenvatinib/everolimus, new agents, and ICI rechallenge.

During a live event, Firas El Chaer, MD, highlighted pivotal data informing decision making in frontline polycythemia vera.

In an in-depth interview, Omar Nadeem, MD, explores the promising findings from 20 patients with smoldering myeloma treated with cilta-cel.

"This [TALAPRO-2] analysis represents the first...patient-level analysis to evaluate rPFS–OS correlation for a PARP inhibitor in first-line mCRPC," said Neeraj Agarwal, MD.

Durvalumab plus BCG induction/maintenance showed a tolerable safety profile in BCG-naive NMIBC, according to the phase 3b PATAPSCO study.

Hafnium oxide nanoparticle radioenhancer adds safely to standard chemoradiotherapy in unresectable stage III NSCLC, showing deep responses and promising early efficacy.

During a live event, Amit Mahipal, MD, and participants discussed first-line treatment selection for unresectable or metastatic hepatocellular carcinoma.

FDA clears HARMONIC trial changes as LP-300 targets EGFR L858R lung cancer after TKI failure, aiming for longer dosing and lower toxicity.

The FDA awarded rare pediatric disease and orphan drug designation to the novel small molecule FL118 for osteosarcoma.

Explore how genomic assays guide personalized early-stage ER+/HER2- breast cancer treatment, weighing Oncotype, MammaPrint, menopausal status, and chemo decisions.